Skip to main content

Codeine (Analgesic) (Monograph)

Drug class: Opiate Agonists
VA class: CN101
CAS number: 41444-62-6

Medically reviewed by Drugs.com on Apr 19, 2023. Written by ASHP.

Warning

Risk Evaluation and Mitigation Strategy (REMS):

FDA approved a REMS for codeine to ensure that the benefits outweigh the risk. The REMS may apply to one or more preparations of codeine and consists of the following: medication guide and elements to assure safe use. See https://www.accessdata.fda.gov/scripts/cder/rems/.

  • FDA drug safety communication (4/13/2023):500 As part of its ongoing efforts to address the nation’s opioid crisis, FDA is requiring several updates to the prescribing information of opioid pain medicines. The changes are being made to provide additional guidance for safe use of these drugs while also recognizing the important benefits when used appropriately. The changes apply to both immediate-release (IR) and extended-release/long-acting preparations (ER/LA).

  • Updates to the IR opioids state that these drugs should not be used for an extended period unless the pain remains severe enough to require an opioid pain medicine and alternative treatment options are insufficient, and that many acute pain conditions treated in the outpatient setting require no more than a few days of an opioid pain medicine.

  • Updates to the ER/LA opioids recommend that these drugs be reserved for severe and persistent pain requiring an extended period of treatment with a daily opioid pain medicine and for which alternative treatment options are inadequate.

  • A new warning is being added about opioid-induced hyperalgesia (OIH) for both IR and ER/LA opioid pain medicines. This includes information describing the symptoms that differentiate OIH from opioid tolerance and withdrawal.

  • Information in the boxed warning for all IR and ER/LA opioid pain medicines will be updated and reordered to elevate the importance of warnings concerning life-threatening respiratory depression, and risks associated with using opioid pain medicines in conjunction with benzodiazepines or other medicines that depress the central nervous system (CNS).

  • Other changes will also be required in various other sections of the prescribing information to educate clinicians, patients, and caregivers about the risks of these drugs.

Introduction

Codeine is a phenanthrene-derivative opiate agonist.

Uses for Codeine (Analgesic)

Codeine is a mild analgesic used in the relief of mild to moderately severe pain122 123 that is not relieved by a nonopiate analgesic. Because of differing mechanisms of action, codeine and aspirin or acetaminophen in combination probably produce additive analgesic effects. Combinations containing codeine, aspirin, and caffeine are effective but produce no more analgesia than a combination of aspirin and codeine.

For use of codeine as an antitussive agent, see 48:08.

Codeine (Analgesic) Dosage and Administration

Administration

Codeine sulfate and codeine phosphate are administered orally.

Dosage

Codeine salts should be given at the lowest effective dosage and for the shortest duration of therapy consistent with the treatment goals of the patient.411 413 431 432 435 Reduced dosage is indicated in poor-risk patients and in very old patients. If concomitant therapy with other CNS depressants is required, the lowest effective dosages and shortest possible duration of concomitant therapy should be used.700 703

When opiate analgesics are administered in fixed combination with nonopiate analgesics, the opiate dosage may be limited by the nonopiate component.117 119 120 121 Because commercially available preparations contain codeine and nonopiate analgesics in various fixed ratios and because these nonopiate analgesics also are available in many other prescription and OTC preparations, care should be taken to ensure that therapy is not duplicated and that dosage of the nonopiate drug does not exceed maximum recommended dosages.117 118 119 121

The initial dosage must be individualized, taking into account the patient’s prior opiate use; concurrent drug therapy; degree of opiate tolerance; medical condition; type and severity of pain; and risk factors for addiction, abuse, and misuse.122 123

For the relief of mild to moderate pain in adults, the usual oral dosage of codeine phosphate or codeine sulfate is 30 mg every 4 hours as necessary; the usual dose range is 15–60 mg. Adult dosage should not exceed 360 mg daily.122 123

Children may receive 3 mg/kg or 100 mg/m2 daily in 6 divided doses. Alternatively, children may be given 0.5 mg/kg or 15 mg/m2 every 4–6 hours. (See Cautions: Pediatric Precautions.)

For acute pain not related to trauma or surgery, the prescribed quantity should be limited to the amount needed for the expected duration of pain severe enough to require opiate analgesia (generally 3 days or less and rarely more than 7 days).411 433 434 435 When opiate analgesics are used for the management of chronic noncancer pain, the US Centers for Disease Control and Prevention (CDC) recommends that primary care clinicians carefully reassess individual benefits and risks before prescribing dosages equivalent to 50 mg or more of morphine sulfate daily (approximately 330 mg or more of codeine phosphate or codeine sulfate daily) and avoid dosages equivalent to 90 mg or more of morphine sulfate daily or carefully justify their decision to titrate the dosage to such levels.411 Other experts recommend consulting a pain management specialist before exceeding a dosage equivalent to 80–120 mg of morphine sulfate daily.423 431

Detailed Codeine dosage information

Cautions for Codeine (Analgesic)

Precautions and Contraindications

Codeine shares the toxic potentials of the opiate agonists, and the usual precautions of opiate agonist therapy should be observed.

Codeine is contraindicated in children younger than 12 years of age for the management of pain705 and in pediatric patients younger than 18 years of age for the management of postoperative pain following tonsillectomy and/or adenoidectomy.122 123 124 130 705 In addition, FDA states that use of codeine for the management of pain is not recommended in pediatric patients 12–18 years of age who are obese or have conditions such as obstructive sleep apnea or compromised respiratory function.705 (See Cautions: Pediatric Precautions.)

Individuals who are ultrarapid metabolizers of cytochrome P-450 (CYP) 2D6 substrates are likely to have higher than expected serum concentrations of morphine, the active metabolite of codeine; therefore, FDA states that codeine should not be used in such patients.705 (See Pharmacokinetics: Pharmacogenomics.)

FDA also states that use of codeine is not recommended in nursing women, especially those who have evidence of ultrarapid metabolism of CYP2D6 substrates.705 Serious adverse events (e.g., excessive sedation, difficulty nursing, respiratory depression), including death, have been reported in nursing infants exposed to codeine.705 One case of opiate toxicity resulting in neonatal death has been reported in the nursing infant of a woman receiving codeine; genetic testing of the woman indicated that she was an ultrarapid metabolizer of codeine.104 105 107 113 705 (See Pharmacokinetics: Pharmacogenomics.) Higher than expected concentrations of morphine were found in breast milk and in the blood of the infant.104 106 107 113 705 Somnolence also has been reported more frequently in nursing infants whose mothers received codeine in combination with acetaminophen compared with those whose mothers received acetaminophen alone; evidence of ultrarapid metabolism of CYP2D6 substrates was identified in some of these women.705 Concentrations of morphine in breast milk are low and dose dependent in women who are normal metabolizers of codeine.705 Although not routinely used in clinical practice, FDA-approved tests (e.g., AmpliChip CYP450 Test) are available to identify an individual’s CYP2D6 genotype.106 111 113 However, testing alone may not adequately predict the risk of adverse reactions.104 113 Infants exposed to codeine through breast milk should be monitored closely for clinical manifestations of opiate toxicity (e.g., sedation, difficulty breast-feeding or breathing, hypotonia).104 105 106 113 705 If such manifestations occur, caregivers should seek immediate medical treatment for the infant.705

When preparations containing codeine in fixed combination with other drugs are administered, the cautions, precautions, and contraindications applicable to each ingredient must be considered.

Pediatric Precautions

Pediatric patients receiving codeine for the management of pain, especially those who are obese, have obstructive sleep apnea or severe lung disease, or have evidence of ultrarapid metabolism of CYP2D6 substrates, are at increased risk of respiratory depression.122 123 130 705 Serious adverse events, including deaths, have been reported during postmarketing experience in pediatric patients receiving codeine.122 123 124 125 126 127 705 Between January 1969 and May 2015, the FDA Adverse Event Reporting System (AERS) received 64 reports of respiratory depression, including 24 reports of death, worldwide that were associated with codeine use in pediatric patients younger than 18 years of age; in all 10 of the reports that provided information about CYP2D6 metabolizer status, the patients were ultrarapid or extensive metabolizers of CYP2D6 substrates.124 705 (See Pharmacokinetics: Pharmacogenomics.) Most of the cases of respiratory depression, including most of the deaths, occurred in children younger than 12 years of age.705 Respiratory depression may occur despite serum concentrations of codeine or morphine being within the therapeutic range; one patient who had concentrations within the therapeutic range died following use of codeine for management of pain after tonsillectomy and adenoidectomy.705

To minimize the risk of serious adverse events in pediatric patients, FDA states that codeine-containing preparations must not be used for the management of pain in children younger than 12 years of age or for the management of postoperative pain following tonsillectomy and/or adenoidectomy in pediatric patients younger than 18 years of age, and that use of codeine for the management of pain is not recommended in pediatric patients 12–18 years of age who are obese or have conditions such as obstructive sleep apnea or compromised respiratory function (because of potentially greater susceptibility to the respiratory depressant effects of the drug).705 If codeine is used for the management of pain in pediatric patients 12–18 years of age, caregivers should closely monitor the child for clinical manifestations of opiate toxicity (e.g., shallow, difficult, or noisy breathing; confusion; unusual sleepiness) and seek immediate medical treatment for the child if such manifestations occur.705

Serious adverse events, including deaths, also have been reported in children receiving codeine for relief of symptoms of upper respiratory tract infection.131 705

Pharmacology

Equianalgesic parenteral doses of codeine phosphate and morphine sulfate have produced similar degrees of respiratory depression. Codeine has good antitussive activity, although on a weight basis antitussive activity of codeine is less than that of morphine.

Codeine (Analgesic) Pharmacokinetics

Codeine and its salts are well absorbed following oral administration. Following oral administration, onset of action occurs in 15–30 minutes and analgesia is maintained for 4–6 hours. Codeine is distributed into milk. Codeine is metabolized mainly in the liver where it undergoes O-demethylation (by cytochrome P-450 [CYP] isoenzyme 2D6), N-demethylation (by CYP3A4), and partial conjugation with glucuronic acid; the drug is excreted mainly in urine as norcodeine and free and conjugated morphine.110 Negligible amounts of codeine and its metabolites are found in feces.

Codeine is metabolized by the CYP microsomal enzyme system, principally by CYP3A4, and to a lesser extent by CYP2D6 (debrisoquine hydroxylase).110 112 Although the CYP2D6 isoenzyme accounts for only 10% of the metabolism of codeine, it plays an essential role in converting the drug to its active O-demethylated metabolite, morphine.108 109 110 112

Pharmacogenomics: Metabolism of certain drugs, including codeine, is influenced by CYP2D6 polymorphism.108 109 110 112 114 Individuals who lack functional alleles of the CYP2D6 gene are described as poor metabolizers, those with 1 or 2 functional alleles are described as extensive metabolizers, and those who carry a duplicate or amplified gene are described as ultrarapid metabolizers.108 109 110 114 Genetically determined differences in drug metabolism can affect an individual’s response to a drug or risk of having an adverse event.108 109 110 112 114 Individuals who are poor metabolizers experience no analgesic effects of codeine;109 individuals who are ultrarapid metabolizers are likely to have higher than expected serum concentrations of morphine.107 109 110 112

Variations in CYP2D6 polymorphism occur at different frequencies among subpopulations of different ethnic or racial origin.107 108 109 110 114 Approximately 1–7% of Caucasians and 10–30% of Ethiopians and Saudi Arabians carry the genotype associated with ultrarapid metabolism of CYP2D6 substrates.107 108 110 114

Chemistry and Stability

Chemistry

Codeine is a phenanthrene-derivative opiate agonist. Codeine occurs as colorless or white crystals or as a white, crystalline powder; the drug is slightly soluble in water and freely soluble in alcohol. Codeine phosphate occurs as fine, white, needle-shaped crystals or as a white, crystalline powder and is freely soluble in water and slightly soluble in alcohol. Codeine sulfate occurs as white crystals, usually needle-like, or as a white, crystalline powder and is soluble in water and very slightly soluble in alcohol.

Stability

Codeine sulfate tablets should be stored in well-closed, light-resistant containers at a temperature less than 40°C, preferably between 15–30°C.

Preparations

Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.

Codeine preparations are subject to control under the Federal Controlled Substances Act of 1970.

Codeine Phosphate

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Bulk

Crystal

Bulk

Powder

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name

Acetaminophen and Codeine Phosphate

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Oral

Solution

120 mg/5 mL Acetaminophen and Codeine Phosphate 12 mg/5 mL*

Acetaminophen and Codeine Phosphate Oral Solution ( C-V )

Tablets

300 mg Acetaminophen and Codeine Phosphate 15 mg*

Acetaminophen and Codeine Phosphate Tablets ( C-III )

300 mg Acetaminophen and Codeine Phosphate 30 mg*

Acetaminophen and Codeine Phosphate Tablets ( C-III )

Tylenol with Codeine No. 3 (C-III)

Janssen

300 mg Acetaminophen and Codeine Phosphate 60 mg*

Acetaminophen and Codeine Phosphate Tablets ( C-III )

Tylenol with Codeine No. 4 (C-III)

Janssen

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name

Other Codeine Phosphate Combinations

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Oral

Capsules

30 mg with Acetaminophen 300 mg, Butalbital 50 mg, and Caffeine 40 mg*

Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules ( C-III )

Fioricet with Codeine (C-III)

Actavis

30 mg with Acetaminophen 325 mg, Butalbital 50 mg, and Caffeine 40 mg*

Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules ( C-III )

30 mg with Aspirin 325 mg, Butalbital 50 mg, and Caffeine 40 mg*

Ascomp with Codeine (C-III)

Nexgen

Butalbital, Aspirin, Caffeine, and Codeine Phosphate Capsules ( C-III )

Fiorinal with Codeine ( C-III )

Allergan

Tablets

16 mg with Aspirin 325 mg and Carisoprodol 200 mg*

Carisoprodol, Aspirin, and Codeine Phosphate Tablets (C-III)

Soma Compound with Codeine (C-III)

Meda

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name

Codeine Sulfate

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Bulk

Powder

Oral

Tablets

15 mg*

Codeine Sulfate Tablets ( C-II )

30 mg*

Codeine Sulfate Tablets ( C-II )

60 mg*

Codeine Sulfate Tablets ( C-II )

AHFS DI Essentials™. © Copyright 2024, Selected Revisions April 19, 2023. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.

References

Only references cited for selected revisions after 1984 are available electronically.

104. Food and Drug Administration. FDA public health advisory: Use of codeine by some breastfeeding mothers may lead to life-threatening side effects in nursing babies. Rockville, MD; 2007 Aug 17. From FDA website http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm054717.htm.

105. Food and Drug Administration. FDA Alert: Use of codeine products in nursing mothers. 2007 Aug 17. From FDA website (http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm118108.htm).

106. Food and Drug Administration. Codeine products used by nursing mothers. Medwatch alert. Rockville, MD; 2007 Aug 17. From FDA website http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm150441.htm.

107. Koren G, Cairns J, Chitayat D et al. Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. Lancet. 2006; 368:704. http://www.ncbi.nlm.nih.gov/pubmed/16920476?dopt=AbstractPlus

108. Kirchheiner J, Schmidt H, Tzvetkov M et al. Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. Pharmacogenomics J. 2007; 7:257-65. http://www.ncbi.nlm.nih.gov/pubmed/16819548?dopt=AbstractPlus

109. Meyer UA. Pharmacogenetics and adverse drug reactions. Lancet. 2000; 356:1667-71. http://www.ncbi.nlm.nih.gov/pubmed/11089838?dopt=AbstractPlus

110. Gasche Y, Daali Y, Fathi M et al. Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N Engl J Med. 2004; 351:2827-31. http://www.ncbi.nlm.nih.gov/pubmed/15625333?dopt=AbstractPlus

111. Roche Molecular Systems, Inc. AmpliChip CYP450 Test for in vitro diagnostic use. Branchburg, NJ; 2007 July.

112. Voronov P, Przybylo HJ, Jagannathan N. Apnea in a child after oral codeine: a genetic variant-an ultra-rapid metabolizer. Paediatr Anaesth. 2007; 17:684-7. http://www.ncbi.nlm.nih.gov/pubmed/17564651?dopt=AbstractPlus

113. Food and Drug Administration. FDA warning on codeine use by nursing mothers. FDA News. Rockville, MD; 2007 Aug 17. From FDA website (http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007).

114. Weinshilboum R. Inheritance and drug response. N Engl J Med. 2003; 348:529-37. http://www.ncbi.nlm.nih.gov/pubmed/12571261?dopt=AbstractPlus

117. Jackson KC II, Lipman AG. Nonopioid analgesics. In: Lipman AG, ed. Pain management for primary care clinicians. Bethesda, MD: American Society of Health-System Pharmacists; 2004:43-58.

118. Cranmer KW, Mason M. Special considerations in geriatric pain management. In: Lipman AG, ed. Pain management for primary care clinicians. Bethesda, MD: American Society of Health-System Pharmacists; 2004:219-232.

119. Fakata KL, Miaskowski C, Lipman AG. Chronic malignant pain. In: Lipman AG, ed. Pain management for primary care clinicians. Bethesda, MD: American Society of Health-System Pharmacists; 2004:139-52.

120. McNicol E, Carr DB. Pharmacological treatment of pain. In: McCarberg B, Passik SD, eds. Expert guide to pain management. Philadelphia: American College of Physicians; 2005:145-78.

121. American Pain Society. Principles of analgesic use in the treatment of acute pain and cancer pain. 5th edition. Glenview, IL; 2003:3,9,13,14.

122. Lannett Company, Inc. Codeine sulfate tablets prescribing information. Philadelphia, PA; 2013 Apr. From DailyMed website

123. TAGI Pharma, Inc. Codeine sulfate oral solution prescribing information. South Beloit, IL; 2013 Apr. From DailyMed website.

124. Food and Drug Administration. Safety review update of codeine use in children; new Boxed Warning and Contraindication on use after tonsillectomy and/or adenoidectomy. FDA News. Rockville, MD; 2013 Feb 20. From FDA website http://www.fda.gov/drugs/drugsafety/ucm339112.htm

125. Kelly LE, Rieder M, van den Anker J et al. More codeine fatalities after tonsillectomy in North American children. Pediatrics. 2012; 129:e1343-7. http://www.ncbi.nlm.nih.gov/pubmed/22492761?dopt=AbstractPlus

126. Ciszkowski C, Madadi P, Phillips MS et al. Codeine, ultrarapid-metabolism genotype, and postoperative death. N Engl J Med. 2009; 361:827-8. http://www.ncbi.nlm.nih.gov/pubmed/19692698?dopt=AbstractPlus

127. Voronov P, Przybylo HJ, Jagannathan N. Apnea in a child after oral codeine: a genetic variant - an ultra-rapid metabolizer. Paediatr Anaesth. 2007; 17:684-7. http://www.ncbi.nlm.nih.gov/pubmed/17564651?dopt=AbstractPlus

128. Yellon RF, Kenna MA, Cladis FP et al. What is the best non-codeine postadenotonsillectomy pain management for children?. Laryngoscope. 2014; :. http://www.ncbi.nlm.nih.gov/pubmed/24867607?dopt=AbstractPlus

129. Prows CA, Zhang X, Huth MM et al. Codeine-related adverse drug reactions in children following tonsillectomy: a prospective study. Laryngoscope. 2014; 124:1242-50. http://www.ncbi.nlm.nih.gov/pubmed/24122716?dopt=AbstractPlus

130. Qualitest Pharmaceuticals. Acetaminophen and codeine phosphate oral solution prescribing information. Huntsville, AL; 2014 Mar. From DailyMed website.

131. European Medicines Agency. Codeine not to be used in children below 12 years for cough and cold. London, UK. 2015 Apr 24. From EMA website. http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Codeine_cough_or_cold_in_children/Position_provided_by_CMDh/WC500186159.pdf

400. US Food and Drug Administration. Drug safety communication: FDA warns about several safety issues with opioid pain medicines; requires label changes. Silver Spring, MD; 2016 Mar 22. From FDA website. http://www.fda.gov/Drugs/DrugSafety/ucm489676.htm

401. Katz N, Mazer NA. The impact of opioids on the endocrine system. Clin J Pain. 2009; 25:170-5. http://www.ncbi.nlm.nih.gov/pubmed/19333165?dopt=AbstractPlus

402. Rajagopal A, Vassilopoulou-Sellin R, Palmer JL et al. Symptomatic hypogonadism in male survivors of cancer with chronic exposure to opioids. Cancer. 2004; 100:851-8. http://www.ncbi.nlm.nih.gov/pubmed/14770444?dopt=AbstractPlus

403. Abs R, Verhelst J, Maeyaert J et al. Endocrine consequences of long-term intrathecal administration of opioids. J Clin Endocrinol Metab. 2000; 85:2215-22. http://www.ncbi.nlm.nih.gov/pubmed/10852454?dopt=AbstractPlus

404. Fraser LA, Morrison D, Morley-Forster P et al. Oral opioids for chronic non-cancer pain: higher prevalence of hypogonadism in men than in women. Exp Clin Endocrinol Diabetes. 2009; 117:38-43. http://www.ncbi.nlm.nih.gov/pubmed/18523930?dopt=AbstractPlus

410. Nuckols TK, Anderson L, Popescu I et al. Opioid prescribing: a systematic review and critical appraisal of guidelines for chronic pain. Ann Intern Med. 2014; 160:38-47. http://www.ncbi.nlm.nih.gov/pubmed/24217469?dopt=AbstractPlus

411. Dowell D, Haegerich TM, Chou R. CDC Guideline for Prescribing Opioids for Chronic Pain - United States, 2016. MMWR Recomm Rep. 2016; 65:1-49. http://www.ncbi.nlm.nih.gov/pubmed/26987082?dopt=AbstractPlus

412. Chou R, Fanciullo GJ, Fine PG et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009; 10:113-30. http://www.ncbi.nlm.nih.gov/pubmed/19187889?dopt=AbstractPlus

413. Management of Opioid Therapy for Chronic Pain Working Group, US Department of Veterans Affairs and Department of Defense. VA/DoD clinical practice guideline for management of opioid therapy for chronic pain. 2010 May. http://www.healthquality.va.gov/guidelines/Pain/cot/COT_312_Full-er.pdf

414. Chou R, Cruciani RA, Fiellin DA et al. Methadone safety: a clinical practice guideline from the American Pain Society and College on Problems of Drug Dependence, in collaboration with the Heart Rhythm Society. J Pain. 2014; 15:321-37. http://www.ncbi.nlm.nih.gov/pubmed/24685458?dopt=AbstractPlus

415. Manchikanti L, Abdi S, Atluri S et al. American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: Part 2--guidance. Pain Physician. 2012; 15(3 Suppl):S67-116.

416. Park TW, Saitz R, Ganoczy D et al. Benzodiazepine prescribing patterns and deaths from drug overdose among US veterans receiving opioid analgesics: case-cohort study. BMJ. 2015; 350:h2698. http://www.ncbi.nlm.nih.gov/pubmed/26063215?dopt=AbstractPlus

417. Jones CM, McAninch JK. Emergency Department Visits and Overdose Deaths From Combined Use of Opioids and Benzodiazepines. Am J Prev Med. 2015; 49:493-501. http://www.ncbi.nlm.nih.gov/pubmed/26143953?dopt=AbstractPlus

418. Dasgupta N, Funk MJ, Proescholdbell S et al. Cohort Study of the Impact of High-Dose Opioid Analgesics on Overdose Mortality. Pain Med. 2016; 17:85-98. http://www.ncbi.nlm.nih.gov/pubmed/26333030?dopt=AbstractPlus

419. Prescription Drug Monitoring Program Training and Technical Assistance Center (PDMP TTAC). Criteria for mandatory enrollment or query of PDMP. From PDMP TTAC website. Accessed 2016 Sep 14. http://www.pdmpassist.org/pdf/Mandatory_Enrollment_Conditions_20171109.pdf

420. National Alliance for Model State Drug Laws (NAMSDL). Overview of state pain management and prescribing policies. From NAMSDL website. Accessed 2016 Sep 14. http://www.namsdl.org/library/74A8658B-E297-9B03-E9AE6218FA0F05B0/

421. Bennett A (Maine Office of Governor). Augusta, ME: 2016 Apr 19. Governor signs major opioid prescribing reform bill. Press release. http://www.maine.gov/governor/lepage/news/index.shtml

422. American Academy of Pain Medicine (AAPM). Use of opioids for the treatment of chronic pain. A statement from the American Academy of Pain Medicine. From AAPM website. 2013 Feb. http://www.painmed.org/files/use-of-opioids-for-the-treatment-of-chronic-pain.pdf

423. Franklin GM, American Academy of Neurology. Opioids for chronic noncancer pain: a position paper of the American Academy of Neurology. Neurology. 2014; 83:1277-84. http://www.ncbi.nlm.nih.gov/pubmed/25267983?dopt=AbstractPlus

424. Dunn KM, Saunders KW, Rutter CM et al. Opioid prescriptions for chronic pain and overdose: a cohort study. Ann Intern Med. 2010; 152:85-92. http://www.ncbi.nlm.nih.gov/pubmed/20083827?dopt=AbstractPlus

425. Gomes T, Mamdani MM, Dhalla IA et al. Opioid dose and drug-related mortality in patients with nonmalignant pain. Arch Intern Med. 2011; 171:686-91. http://www.ncbi.nlm.nih.gov/pubmed/21482846?dopt=AbstractPlus

426. Bohnert AS, Valenstein M, Bair MJ et al. Association between opioid prescribing patterns and opioid overdose-related deaths. JAMA. 2011; 305:1315-21. http://www.ncbi.nlm.nih.gov/pubmed/21467284?dopt=AbstractPlus

429. Paice JA, Portenoy R, Lacchetti C et al. Management of Chronic Pain in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016; 34:3325-45. http://www.ncbi.nlm.nih.gov/pubmed/27458286?dopt=AbstractPlus

430. Chou R, Gordon DB, de Leon-Casasola OA et al. Management of Postoperative Pain: A Clinical Practice Guideline From the American Pain Society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists' Committee on Regional Anesthesia, Executive Committee, and Administrative Council. J Pain. 2016; 17:131-57. http://www.ncbi.nlm.nih.gov/pubmed/26827847?dopt=AbstractPlus

431. Washington State Agency Medical Directors' Group (AMDG). Interagency guideline on prescribing opioids for pain, 3rd ed. From Washington State AMDG website. 2015 Jun. http://www.agencymeddirectors.wa.gov/Files/2015AMDGOpioidGuideline.pdf

432. Hegmann KT, Weiss MS, Bowden K et al. ACOEM practice guidelines: opioids for treatment of acute, subacute, chronic, and postoperative pain. J Occup Environ Med. 2014; 56:e143-59.

433. Cantrill SV, Brown MD, Carlisle RJ et al. Clinical policy: critical issues in the prescribing of opioids for adult patients in the emergency department. Ann Emerg Med. 2012; 60:499-525. http://www.ncbi.nlm.nih.gov/pubmed/23010181?dopt=AbstractPlus

434. Thorson D, Biewen P, Bonte B et al, for Institute for Clinical Systems Improvement (ICSI). Acute pain assessment and opioid prescribing protocol. From ICSI website. 2014 Jan. https://www.icsi.org

435. New York City Department of Health and Mental Hygiene. New York City emergency department discharge opioid prescribing guidelines. From NYC Health website. 2013 Jan. http://www1.nyc.gov/assets/doh/downloads/pdf/basas/opioid-prescribing-guidelines.pdf

436. Chou R, Deyo R, Devine B et al. The effectiveness and risks of long-term opioid treatment of chronic pain. Evidence report/technology assessment No. 218. Rockville, MD: Agency for Healthcare Research and Quality (AHRQ); 2014 Sep. https://effectivehealthcare.ahrq.gov/sites/default/files/pdf/chronic-pain-opioid-treatment_research.pdf

500. FDA drug safety communication . FDA updates prescribing information for all opioid pain medicines to provide additional guidance for safe use Includes updates to help reduce unnecessary prescribing; issued Apr 13 2023. From FDA website. https://www.fda.gov/media/167058/download

700. US Food and Drug Administration. Drug safety communication: FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning. Silver Spring, MD; 2016 Aug 31. From FDA website. https://www.fda.gov/drugs/drugsafety/ucm518473.htm

701. Jones CM, Mack KA, Paulozzi LJ. Pharmaceutical overdose deaths, United States, 2010. JAMA. 2013; 309:657-9. http://www.ncbi.nlm.nih.gov/pubmed/23423407?dopt=AbstractPlus

702. Jones CM, Paulozzi LJ, Mack KA et al. Alcohol involvement in opioid pain reliever and benzodiazepine drug abuse-related emergency department visits and drug-related deaths - United States, 2010. MMWR Morb Mortal Wkly Rep. 2014; 63:881-5. http://www.ncbi.nlm.nih.gov/pubmed/25299603?dopt=AbstractPlus

703. Hertz S. Letter to manufacturers of opioid analgesics: safety labeling change notification. Silver Spring, MD: US Food and Drug Administration. Accessed 2017 Mar 20. https://www.fda.gov/downloads/Drugs/DrugSafety/InformationbyDrugClass/UCM518611.pdf

704. Seymour S. Letter to manufacturers of opioid antitussives: safety labeling change notification. Silver Spring, MD: US Food and Drug Administration. Accessed 2017 Mar 20. https://www.fda.gov/downloads/Drugs/DrugSafety/InformationbyDrugClass/UCM518612.pdf

705. Food and Drug Administration. Drug safety communication: FDA restricts use of prescription codeine pain and cough medicines and tramadol pain medicines in children; recommends against use in breastfeeding women. Silver Spring, MD; 2017 Apr 20. From FDA website. https://www.fda.gov/downloads/Drugs/DrugSafety/UCM553814.pdf

706. Janssen Pharmaceuticals, Inc. Tylenol with Codeine (acetaminophen and codeine phosphate) tablets prescribing information. Titusville, NJ; 2017 Jan.

750. Food and Drug Administration. FDA Drug Safety Communication: FDA recommends health care professionals discuss naloxone with all patients when prescribing opioid pain relievers or medicines to treat opioid use disorder; consider prescribing naloxone to those at increased risk of opioid overdose. 2020 Jul 23. From FDA website. Accessed 2020 Jul 28. https://www.fda.gov/media/140360/download

Frequently asked questions

View more FAQ

Medical Disclaimer